Collaborative review: factors influencing treatment decisions for patients with a localized solid renal mass
T Chandrasekar, SA Boorjian, U Capitanio… - European urology, 2021 - Elsevier
Context With the addition of active surveillance and thermal ablation (TA) to the urologist's
established repertoire of partial (PN) and radical nephrectomy (RN) as first-line …
established repertoire of partial (PN) and radical nephrectomy (RN) as first-line …
European association of urology guidelines on renal cell carcinoma: the 2019 update
B Ljungberg, L Albiges, Y Abu-Ghanem, K Bensalah… - European urology, 2019 - Elsevier
Abstract Context The European Association of Urology Renal Cell Carcinoma (RCC)
Guideline Panel has prepared evidence-based guidelines and recommendations for the …
Guideline Panel has prepared evidence-based guidelines and recommendations for the …
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
B Escudier, C Porta, M Schmidinger… - Annals of …, 2019 - annalsofoncology.org
Kidney cancer accounts for 5% and 3% of all adult malignancies in men and women,
respectively, thus representing the 7th most common cancer in men, and the 10th most …
respectively, thus representing the 7th most common cancer in men, and the 10th most …
French AFU Cancer Committee Guidelines-update 2022-2024: management of kidney cancer
P Bigot, P Barthelemy, R Boissier, ZE Khene… - Progrès en Urologie, 2022 - Elsevier
Aim To update the recommendations for the management of kidney cancers. Methods A
systematic review of the literature was conducted from 2015 to 2022. The most relevant …
systematic review of the literature was conducted from 2015 to 2022. The most relevant …
[HTML][HTML] RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or …
B Oza, E Frangou, B Smith, H Bryant, R Kaplan… - Contemporary Clinical …, 2021 - Elsevier
Abstract Background 20–60% of patients with initially locally advanced Renal Cell
Carcinoma (RCC) develop metastatic disease despite optimal surgical excision. Adjuvant …
Carcinoma (RCC) develop metastatic disease despite optimal surgical excision. Adjuvant …
The impact of histological subtype on the incidence, timing, and patterns of recurrence in patients with renal cell carcinoma after surgery—results from RECUR …
Y Abu-Ghanem, T Powles, U Capitanio… - European urology …, 2021 - Elsevier
Background Current follow-up strategies for patients with renal cell carcinoma (RCC) after
curative surgery rely mainly on risk models and the treatment delivered, regardless of the …
curative surgery rely mainly on risk models and the treatment delivered, regardless of the …
Prevalence, disease-free, and overall survival of contemporary patients with renal cell carcinoma eligible for adjuvant checkpoint inhibitor trials
L Marconi, M Sun, C Beisland, T Klatte… - Clinical Genitourinary …, 2021 - Elsevier
Introduction Designing adjuvant trials is challenging because of uncertainties of prevalence
and outcome of high-risk renal cell cancer (RCC) despite use of validated risk scores. Our …
and outcome of high-risk renal cell cancer (RCC) despite use of validated risk scores. Our …
Biomarkers for renal cell carcinoma recurrence: state of the art
M Marchioni, JG Rivas, A Autran, M Socarras… - Current Urology …, 2021 - Springer
Abstract Purpose of Review We aim to summarize the current state of art about the possible
use of biomarkers for predicting renal cell carcinoma (RCC) recurrence after curative …
use of biomarkers for predicting renal cell carcinoma (RCC) recurrence after curative …
Circular RNAs in clear cell renal cell carcinoma: their microarray-based identification, analytical validation, and potential use in a clinico-genomic model to improve …
A Franz, B Ralla, S Weickmann, M Jung, H Rochow… - Cancers, 2019 - mdpi.com
Circular RNAs (circRNAs) may act as novel cancer biomarkers. However, a genome-wide
evaluation of circRNAs in clear cell renal cell carcinoma (ccRCC) has yet to be conducted …
evaluation of circRNAs in clear cell renal cell carcinoma (ccRCC) has yet to be conducted …
Extracellular vesicles enriched in hsa-miR-301a-3p and hsa-miR-1293 dynamics in clear cell renal cell carcinoma patients: potential biomarkers of metastatic disease
F Dias, AL Teixeira, I Nogueira, M Morais, J Maia… - Cancers, 2020 - mdpi.com
Clear cell renal cell carcinoma (ccRCC) is the most aggressive subtype of kidney cancer
and up to 40% of patients submitted to surgery with a curative intent will relapse. Thus, the …
and up to 40% of patients submitted to surgery with a curative intent will relapse. Thus, the …